Molecular approaches to resolve diagnostic dilemmas: The case of gastrointestinal stromal tumor and leiomyosarcoma

Jonathan Trent, Alexander J F Lazar, Wei Zhang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) and leiomyosarcomas (LMSs) are common types of mesenchymal tumors that may present a diagnostic challenge. GISTs have frequent overexpression of Kit and often encode for mutation of the KIT oncogene. In addition, patients usually experience a favorable response to targeted therapy with imatinib mesylate (Gleevec®, STI-571), but not cytotoxic chemotherapy. Up to 5% of GISTs can be completely negative for Kit on immunohistochemistry. Conversely, LIMSs may rarely express Kit, but are virtually never associated with an activating KIT mutation, and are often effectively treated with cytotoxic chemotherapy but are resistant to imatinib. To aid in resolution of this clincal challenge, we performed a whole-genome gene expression study on 71 well-defined GIST and LMS samples with development of a robust, novel approach to molecular classification discussed herein.

Original languageEnglish
Pages (from-to)629-637
Number of pages9
JournalFuture Oncology
Volume3
Issue number6
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Leiomyosarcoma
Drug Therapy
Mutation
Oncogenes
Immunohistochemistry
Genome
Gene Expression
Imatinib Mesylate
Neoplasms
Therapeutics

Keywords

  • Clinical
  • Diagnosis
  • Gastrointestinal
  • GIST
  • Imatinib
  • Leiomyosarcoma
  • Microarray
  • Sarcoma
  • Sunitinib
  • Targeted therapy
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Molecular approaches to resolve diagnostic dilemmas : The case of gastrointestinal stromal tumor and leiomyosarcoma. / Trent, Jonathan; Lazar, Alexander J F; Zhang, Wei.

In: Future Oncology, Vol. 3, No. 6, 01.12.2007, p. 629-637.

Research output: Contribution to journalArticle

Trent, Jonathan ; Lazar, Alexander J F ; Zhang, Wei. / Molecular approaches to resolve diagnostic dilemmas : The case of gastrointestinal stromal tumor and leiomyosarcoma. In: Future Oncology. 2007 ; Vol. 3, No. 6. pp. 629-637.
@article{d9a704a363234567884be54c1ba98e2d,
title = "Molecular approaches to resolve diagnostic dilemmas: The case of gastrointestinal stromal tumor and leiomyosarcoma",
abstract = "Gastrointestinal stromal tumors (GISTs) and leiomyosarcomas (LMSs) are common types of mesenchymal tumors that may present a diagnostic challenge. GISTs have frequent overexpression of Kit and often encode for mutation of the KIT oncogene. In addition, patients usually experience a favorable response to targeted therapy with imatinib mesylate (Gleevec{\circledR}, STI-571), but not cytotoxic chemotherapy. Up to 5{\%} of GISTs can be completely negative for Kit on immunohistochemistry. Conversely, LIMSs may rarely express Kit, but are virtually never associated with an activating KIT mutation, and are often effectively treated with cytotoxic chemotherapy but are resistant to imatinib. To aid in resolution of this clincal challenge, we performed a whole-genome gene expression study on 71 well-defined GIST and LMS samples with development of a robust, novel approach to molecular classification discussed herein.",
keywords = "Clinical, Diagnosis, Gastrointestinal, GIST, Imatinib, Leiomyosarcoma, Microarray, Sarcoma, Sunitinib, Targeted therapy, Treatment",
author = "Jonathan Trent and Lazar, {Alexander J F} and Wei Zhang",
year = "2007",
month = "12",
day = "1",
doi = "10.2217/14796694.3.6.629",
language = "English",
volume = "3",
pages = "629--637",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Molecular approaches to resolve diagnostic dilemmas

T2 - The case of gastrointestinal stromal tumor and leiomyosarcoma

AU - Trent, Jonathan

AU - Lazar, Alexander J F

AU - Zhang, Wei

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Gastrointestinal stromal tumors (GISTs) and leiomyosarcomas (LMSs) are common types of mesenchymal tumors that may present a diagnostic challenge. GISTs have frequent overexpression of Kit and often encode for mutation of the KIT oncogene. In addition, patients usually experience a favorable response to targeted therapy with imatinib mesylate (Gleevec®, STI-571), but not cytotoxic chemotherapy. Up to 5% of GISTs can be completely negative for Kit on immunohistochemistry. Conversely, LIMSs may rarely express Kit, but are virtually never associated with an activating KIT mutation, and are often effectively treated with cytotoxic chemotherapy but are resistant to imatinib. To aid in resolution of this clincal challenge, we performed a whole-genome gene expression study on 71 well-defined GIST and LMS samples with development of a robust, novel approach to molecular classification discussed herein.

AB - Gastrointestinal stromal tumors (GISTs) and leiomyosarcomas (LMSs) are common types of mesenchymal tumors that may present a diagnostic challenge. GISTs have frequent overexpression of Kit and often encode for mutation of the KIT oncogene. In addition, patients usually experience a favorable response to targeted therapy with imatinib mesylate (Gleevec®, STI-571), but not cytotoxic chemotherapy. Up to 5% of GISTs can be completely negative for Kit on immunohistochemistry. Conversely, LIMSs may rarely express Kit, but are virtually never associated with an activating KIT mutation, and are often effectively treated with cytotoxic chemotherapy but are resistant to imatinib. To aid in resolution of this clincal challenge, we performed a whole-genome gene expression study on 71 well-defined GIST and LMS samples with development of a robust, novel approach to molecular classification discussed herein.

KW - Clinical

KW - Diagnosis

KW - Gastrointestinal

KW - GIST

KW - Imatinib

KW - Leiomyosarcoma

KW - Microarray

KW - Sarcoma

KW - Sunitinib

KW - Targeted therapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=38049150540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049150540&partnerID=8YFLogxK

U2 - 10.2217/14796694.3.6.629

DO - 10.2217/14796694.3.6.629

M3 - Article

C2 - 18041915

AN - SCOPUS:38049150540

VL - 3

SP - 629

EP - 637

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 6

ER -